account_id none on file
legal_name Nautilus Biotechnology, Inc.
ticker NAUT
cik 1808805
domain nautilus.bio
linkedin_company_url https://www.linkedin.com/company/nautilus-biotechnology/
entry_point_account_id none on file
name Nautilus Biotechnology Inc.
exchange Nasdaq
sector Industrials
sector index/company/sector/industrials/
calls 1 filings 0 executives 2 family 0
why_nownone on file
calls
For the third quarter of 2025, total operating expenses were $15.5 million, down from $19.1 million in the same quarter of 2024. This 19% year-over-year decrease reflects our continued focus on expense management, operating efficiency, and lower development costs overall.
Oct 28, 2025 / receipt, needs a key / Anna Mowry, CFO | earnings call 2025-10-28 | transcript 55f86717-267f-406e-9feb-b2bb116a4d10 | chars 12945-13217 | segment 13
filingsnone on file
executives
| Anna Mowry | CFO | - | receipt |
| Sujal Patel | CEO | - | receipt |
familynone on file
upcoming
| 2026-10-26 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug nautilus-biotechnology-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$